Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 77,862
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12589087 | Enantiomer selective action on neurotransmission | 🖼🧊📄§ | 2026-03-31 | 2042-04-01 | 0 | 31 |
| 12589083 | Abuse-deterrent dosage forms containing esketamine | 🖼🧊📄§ | 2026-03-31 | 2041-11-10 | 0 | 31 |
| 12589090 | Compounds and methods for the treatment of degenerative disorders | 🖼🧊📄§ | 2026-03-31 | 2040-01-21 | 0 | 31 |
| 12589089 | PTGDR-1 and/or PTGDR-2 antagonists for preventing and/or treating systemic lupus erythematosus | 🖼🧊📄§ | 2026-03-31 | 2044-03-12 | 0 | 31 |
| 12589091 | Topical formulation comprising sirolimus | 🖼🧊📄§ | 2026-03-31 | 2042-02-09 | 0 | 31 |
| 12589093 | Plasma kallikrein inhibitors and methods of use thereof in ocular disorders | 🖼🧊📄§ | 2026-03-31 | 2040-04-08 | 0 | 31 |
| 12589097 | Apilimod compositions and methods of use | 🖼🧊📄§ | 2026-03-31 | 2043-08-03 | 0 | 31 |
| 12589095 | Unit dosage form for transmucosal drug delivery of an active pharmaceutical ingredient | 🖼🧊📄§ | 2026-03-31 | 2040-05-29 | 0 | 31 |
| 12589099 | Alpha-1062 for treating traumatic brain injury | 🖼🧊📄§ | 2026-03-31 | 2042-11-25 | 0 | 31 |
| 12589100 | Halobetasol foam composition and method of manufacture thereof | 🖼🧊📄§ | 2026-03-31 | 2039-08-19 | 0 | 31 |
| 12589102 | Injectable sustained-release formulations for treatment of joint pain and inflammation | 🖼🧊📄§ | 2026-03-31 | 2040-05-06 | 0 | 31 |
| 12589105 | Human milk fortifier composition | 🖼🧊📄§ | 2026-03-31 | 2039-12-17 | 0 | 31 |
| 12589106 | Nutritional composition comprising a combination of human milk oligosaccharides to improve the gastrointestinal barrier | 🖼🧊📄§ | 2026-03-31 | 2039-12-11 | 0 | 31 |
| 12589108 | Injectable bifunctional hydrogel with antibacterial activity as well as the preparative method and the use thereof | 🖼🧊📄§ | 2026-03-31 | 2040-05-29 | 0 | 31 |
| 12589111 | Pt(IV) chemotherapeutic prodrug and controlled release thereof for treatment of tumors | 🖼🧊📄§ | 2026-03-31 | 2041-11-24 | 0 | 31 |
| 12589107 | Composition containing nicotinamide mononucleotide and mogroside, and application thereof | 🖼🧊📄§ | 2026-03-31 | 2039-03-14 | 0 | 31 |
| 12589112 | Oncolytic virus compositions including IL-15 complex and methods for the treatment of cancer | 🖼🧊📄§ | 2026-03-31 | 2041-01-22 | 0 | 31 |
| 12589118 | Method of prolonging the lifespan of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) using a cerebrolysin® preparation | 🖼🧊📄§ | 2026-03-31 | 2038-08-28 | 0 | 31 |
| 12589117 | Mesenchymal stem cell-derived extracellular vesicles and uses thereof for treating and diagnosing fibrotic diseases | 🖼🧊📄§ | 2026-03-31 | 2042-07-18 | 0 | 31 |
| 12589116 | Method for producing umbilcal cord blood-derived stem cell with enhanced efficacy | 🖼🧊📄§ | 2026-03-31 | 2040-12-16 | 0 | 31 |
| 12589119 | Treatment of cachexia using fibroblast cells and products thereof | 🖼🧊📄§ | 2026-03-31 | 2039-11-04 | 0 | 31 |
| 12589120 | Methods of treating epidermolysis bullosa with cell-free amniotic fluid compositions | 🖼🧊📄§ | 2026-03-31 | 2042-10-12 | 0 | 31 |
| 12589123 | Compositions and methods comprising clostridium butyricum for the treatment of cancer | 🖼🧊📄§ | 2026-03-31 | 2041-04-20 | 0 | 31 |
| 12589126 | Composition of stimulating immunity comprising Lactobacillus rhamnosus LM1019 and starter strains | 🖼🧊📄§ | 2026-03-31 | 2044-01-23 | 0 | 31 |
| 12589128 | Oncolytic adenovirus compositions | 🖼🧊📄§ | 2026-03-31 | 2041-07-09 | 0 | 31 |
| 12589131 | Use of collagen hydrolysate in prevention and/or treatment of food craving | 🖼🧊📄§ | 2026-03-31 | 2043-02-01 | 0 | 31 |
| 12589130 | Aloe extracts for microbial neutralisation | 🖼🧊📄§ | 2026-03-31 | 2043-04-19 | 0 | 31 |
| 12589129 | Polyherbal metallo-mineral pharmaceutical kit | 🖼🧊📄§ | 2026-03-31 | 2041-07-13 | 0 | 31 |
| 12589138 | Marker for acid sphingomyelinase disorders and uses thereof | 🖼🧊📄§ | 2026-03-31 | 2044-04-29 | 0 | 31 |
| 12589137 | Compositions and methods for treating pathological calcification and ossification | 🖼🧊📄§ | 2026-03-31 | 2042-01-28 | 0 | 31 |
| 12589141 | DNA vaccine capable of effectively treating and/or preventing type 1 diabetes and use thereof | 🖼🧊📄§ | 2026-03-31 | 2040-03-02 | 0 | 31 |
| 12589140 | Antigen-presenting neutrophil-derived dendritic cells and methods of use thereof | 🖼🧊📄§ | 2026-03-31 | 2040-01-22 | 0 | 31 |
| 12589142 | HLA tumor antigen peptides of class I and II for treating mammary/breast carcinomas | 🖼🧊📄§ | 2026-03-31 | 2040-06-02 | 0 | 31 |
| 12589143 | Human anti-PD-L1 peptide vaccines and methods of their use | 🖼🧊📄§ | 2026-03-31 | 2040-09-17 | 0 | 31 |
| 12589144 | Combined norovirus and rotavirus vaccine composition and methods of preparation | 🖼🧊📄§ | 2026-03-31 | 2041-01-06 | 0 | 31 |
| 12589146 | Adjuvanted protein vaccines comprising modified full-length spike protein of SARS-CoV-2 composition and methods of use | 🖼🧊📄§ | 2026-03-31 | 2043-02-22 | 0 | 31 |
| 12589151 | T cell modification | 🖼🧊📄§ | 2026-03-31 | 2039-11-29 | 0 | 31 |
| 12589150 | Antibodies binding AXL | 🖼🧊📄§ | 2026-03-31 | 2043-02-28 | 0 | 31 |
| 12589149 | Method of modulating mucosal immunogenicity | 🖼🧊📄§ | 2026-03-31 | 2040-03-18 | 0 | 31 |
| 12589155 | Efficient synthesis of lipid-fluorescein conjugates for CAR-T cell therapy | 🖼🧊📄§ | 2026-03-31 | 2040-07-02 | 0 | 31 |
| 12589157 | Compositions of drug delivery agents and methods of use thereof | 🖼🧊📄§ | 2026-03-31 | 2039-03-29 | 0 | 31 |
| 12589160 | Peptide-derived therapeutics targeting KDM5C for the treatment of cancer | 🖼🧊📄§ | 2026-03-31 | 2040-03-12 | 0 | 31 |
| 12589163 | Shedding blocking agents with increased stability | 🖼🧊📄§ | 2026-03-31 | 2041-03-11 | 0 | 31 |
| 12589161 | PEGylated synthetic KL4 peptide, compositions and methods thereof | 🖼🧊📄§ | 2026-03-31 | 2040-07-10 | 0 | 31 |
| 12589162 | Trans-cyclooctene prodrug of monomethyl auristatin E | 🖼🧊📄§ | 2026-03-31 | 2041-08-06 | 0 | 31 |
| 12589165 | Methods for treating bladder tumors with viral nanoparticle conjugates and immune checkpoint inhibitors | 🖼🧊📄§ | 2026-03-31 | 2038-04-11 | 0 | 31 |
| 12589166 | Compositions and methods for treating wounds | 🖼🧊📄§ | 2026-03-31 | 2041-05-13 | 0 | 31 |
| 12589170 | Devices and methods for radiopharmaceutical synthesis | 🖼🧊📄§ | 2026-03-31 | 2040-04-07 | 0 | 31 |
| 12589169 | Compound and MRI contrast agent containing same | 🖼🧊📄§ | 2026-03-31 | 2041-10-05 | 0 | 31 |
| 12589171 | 177-Lu labeled peptide for site-specific uPAR-targeting | 🖼🧊📄§ | 2026-03-31 | 2041-01-07 | 0 | 31 |